Omkar Pharmachem
Ticker > Company >

Omkar Pharmachem share price

Omkar Pharmachem Ltd.

BSE: 532167 SECTOR: Pharmaceuticals & Drugs  5.96 K   1   0

25.56
0 0
BSE: 12 Sep 04:00 PM

Price Summary

Today's High

₹ 25.56

Today's Low

₹ 25.56

52 Week High

₹ 30.09

52 Week Low

₹ 25.56

FinStar is Suspended!

The FinStar rating for this company is currently unavailable due to limited data disclosure. As a micro-cap company, it may carry higher risk and limited transparency. We will update the FinStar rating once more reliable data becomes available.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

₹ 25.78 Cr.

Enterprise Value

₹ 26.01 Cr.

No. of Shares

1.01 Cr.

P/E

145.64

P/B

2.72

Face Value

₹ 10

Div. Yield

0 %

Book Value (TTM)

₹  9.38

CASH

₹ 0.07 Cr.

DEBT

₹ 0.3 Cr.

Promoter Holding

0.03 %

EPS (TTM)

₹  0.18

Sales Growth

0%

ROE

2.07 %

ROCE

2.94%

Profit Growth

-4.4 %

Add Your Ratio

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.

PE Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

PB Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year0%
3 Year25.99%
5 Year∞%

Profit Growth

1 Year-4.4%
3 Year-5.12%
5 Year19.63%

ROE%

1 Year2.07%
3 Year2.12%
5 Year1.19%

ROCE %

1 Year2.94%
3 Year2.97%
5 Year1.38%

Debt/Equity

0.0328

Price to Cash Flow

87.2

Interest Cover Ratio

9.6575

CFO/PAT (5 Yr. Avg.)

1.09608875517112

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Jun 2025 0.03 0.00
Mar 2025 0.03 0.00
Dec 2024 0.03 0.00
Sep 2024 0.03 0.00
Jun 2024 0.03 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has shown a good revenue growth of 25.9918138862491% for the Past 3 years.
  • The company has significantly decreased its debt by 0.3183 Cr.
  • Company is virtually debt free.
  • The company has an efficient Cash Conversion Cycle of 60.225 days.
  • The company has a good cash flow management; CFO/PAT stands at 1.09608875517112.
  • The company has a strong degree of Operating leverage, Average Operating leverage stands at 3.94391025641027.

 Limitations

  • The company has shown a poor profit growth of -5.1207366579242% for the Past 3 years.
  • Company has a poor ROE of 2.12408119476524% over the past 3 years.
  • Company has a poor ROCE of 2.96662761137567% over the past 3 years
  • The company has a low EBITDA margin of -57.259254074074% over the past 5 years.
  • The company is trading at a high PE of 145.64.
  • The company is trading at a high EV/EBITDA of 92.7545.

Quarterly Result (All Figures in Cr.)

PARTICULARS Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025
Net Sales 0.14 0.14 0.14 0.14 0.14
Total Expenditure 0.09 0.05 0.05 0.07 0.1
Operating Profit 0.05 0.09 0.08 0.07 0.04
Other Income 0 0 0 0 0
Interest 0 0 0 0.02 0
Depreciation 0 0 0 0 0
Exceptional Items 0 0 0 0 0
Profit Before Tax 0.05 0.09 0.08 0.05 0.04
Tax 0 0 0 0.07 0.01
Profit After Tax 0.05 0.09 0.08 -0.02 0.03
Adjusted EPS (Rs) 0.05 0.09 0.08 -0.02 0.03

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Net Sales 0.05 0.27 0.54 0.54 0.54
Total Expenditure 0.25 0.25 0.27 0.23 0.26
Operating Profit -0.2 0.02 0.27 0.31 0.28
Other Income 0 0 0 0 0
Interest 0.05 0.06 0.06 0.05 0.03
Depreciation 0 0 0 0 0
Exceptional Items 0 0 0 0 0
Profit Before Tax -0.26 -0.04 0.21 0.26 0.25
Tax 0 -0.26 0.03 0.07 0.06
Net Profit -0.26 0.22 0.18 0.2 0.19
Adjusted EPS (Rs.) -0.26 0.22 0.18 0.2 0.19

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity and Liabilities
Share Capital 10.08 10.08 10.08 10.08 10.08
Total Reserves -1.64 -1.42 -1.24 -1.04 -0.85
Borrowings 0 0 0 0 0
Other N/C liabilities 0 -0.26 -0.23 -0.16 -0.1
Current liabilities 0.92 0.97 0.98 0.69 0.36
Total Liabilities 9.36 9.37 9.6 9.57 9.49
Assets
Net Block 0 0 0.01 0 0.01
Capital WIP 0 0 0 0 0
Intangible WIP 0 0 0 0 0
Investments 9.3 9.3 9.3 9.3 9.3
Loans & Advances 0 0 0 0 0
Other N/C Assets 0 0 0 0 0
Current Assets 0.06 0.07 0.29 0.26 0.18
Total Assets 9.36 9.37 9.6 9.57 9.49
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Profit from operations -0.26 -0.04 0.21 0.26 0.25
Adjustment 0.05 0.06 0.06 0.05 0.03
Changes in Assets & Liabilities -0.01 0 -0.07 -0.04 0.01
Tax Paid 0 0 0 0 0
Operating Cash Flow -0.21 0.02 0.2 0.28 0.3
Investing Cash Flow 0 0 -0.01 0 -0.01
Financing Cash Flow 0.24 -0.02 -0.03 -0.35 -0.35
Net Cash Flow 0.02 0 0.17 -0.08 -0.06

Corporate Actions

Investors Details

PARTICULARS Jun 2024% Sep 2024% Dec 2024% Mar 2025% Jun 2025%
promoters 0.03 0.03 0.03 0.03 0.03
dipakkumar mulchandbhai v... 0.01 0.01 0.01 0.01 0.01
shah kirtikumar laxmichan... 0.02 0.02 0.02 0.02 0.02
PARTICULARS Jun 2024% Sep 2024% Dec 2024% Mar 2025% Jun 2025%
investors 99.97 99.97 99.97 99.97 99.97
ahsan ali khan 1.83 1.83 1.83 1.83 1.83
akshay saxena 1.98 1.98 1.98 1.98 1.98
anand sharma 1.54 1.54 1.54 1.54 1.54
arvind singh rathore 1.04 1.04 1.04 1.04 1.04
ashok kumar bhatia 1.49 1.49 1.49 1.49 1.49
ashok kumar tiwari 1.64 1.64 1.64 1.64 1.64
avtar singh 1.56 1.56 1.56 1.56 1.56
bhag singh 2.48 2.48 2.48 2.48 2.48
davinder kaur - - - - 1.29
gujarat state financial c... 1.49 1.49 1.49 1.49 1.49
gyan kaur 1.63 1.63 1.63 1.63 1.63
harvinder singh chadha 1.12 1.12 1.12 1.12 1.12
jagdish chand bhatia 1.29 1.29 1.29 1.29 1.29
jaspal singh . 1.12 - 1.12 - 1.12
jitender singh 1.74 1.74 1.74 1.74 1.74
kailash nath singh 1.49 1.49 1.49 1.49 1.49
kimati kumar singh 1.63 1.63 1.63 1.63 1.63
kuldeep singh 3.72 3.72 3.72 3.72 3.72
laiqu ahmad ansari 1.49 1.49 1.49 1.49 1.49
manmeet chadha 1.56 1.56 1.56 1.56 1.56
manoj kumar singh 1.76 1.76 1.76 1.76 1.76
navneet kumar saxena 1.93 1.93 1.93 1.93 1.93
radheshyam yadav 1.74 1.74 1.74 1.74 1.74
resam singh 2.48 2.48 2.48 2.48 2.48
roshan lal 1.11 1.11 1.11 1.11 1.11
rupesh chauhan 1.59 1.59 1.59 1.59 1.59
sanjeev saxena 2.94 2.94 2.94 2.94 2.94
shailesh sharma 1.41 1.41 1.41 1.41 1.41
shilendra yadav 1.64 1.64 1.64 1.64 1.64
vijay sharma 1.40 1.40 1.40 1.40 1.40
har kishan singh 1.29 1.29 1.29 1.29 -
jaspal singh - 1.12 - 1.12 -

Annual Reports

Title Link
Title Link
Annual Report 2019
Annual Report 2018
Annual Report 2017

Ratings & Research Reports

TYPE AGENCY Link
TYPE AGENCY Link
 No Credit reports exist for this company.Report us
TYPE AGENCY Link
TYPE AGENCY Link
 No Research reports exist for this company.Report us

Concalls & Presentations

TYPE QUARTER Link
TYPE QUARTER Link
 Currently we do not have any Concall related to this company.Report us
TYPE QUARTER Link
TYPE QUARTER Link
 Currently we do not have any Presentation related to this company.Report us

Omkar Pharmachem Stock Price Analysis and Quick Research Report. Is Omkar Pharmachem an attractive stock to invest in?

Stock investing requires careful analysis of financial data to determine a company's true net worth. This is generally done by examining the company's profit and loss account, balance sheet and cash flow statement, which can be time-consuming and cumbersome.

Examining a company's financial ratios is an easier way to determine its performance, which can help to make sense of the overwhelming amount of information in its financial statements. 

Here are a few indispensable ratios that should be a part of every investor’s research process, or, in simpler words, how to analyse Omkar Pharmachem. 

  • PE ratio: Price to Earnings ratio, which indicates how much an investor is willing to pay for a share for every rupee of earnings. A general rule of thumb is that shares trading at a low P/E are undervalued (it depends on other factors too). Omkar Pharmachem has a PE ratio of 145.641025641026 which is high and comparatively overvalued.

  • Return on Assets (ROA): Return on Assets measures how effectively a company can earn a return on its investment in assets. In other words, ROA shows how efficiently a company can convert the money used to purchase assets into net income or profits. Omkar Pharmachem has ROA of 1.9844% which is a bad sign for future performance. (Higher values are always desirable.)

  • Current ratio: The current ratio measures a company's ability to pay its short-term liabilities with its short-term assets. A higher current ratio is desirable so that the company could be stable to unexpected bumps in business and economy. Omkar Pharmachem has a Current ratio of 0.512.

  • Return on equity: ROE measures the ability of a firm to generate profits from its shareholders' investments in the company. In other words, the return on equity ratio shows how much profit each rupee of common stockholders’ equity generates. Omkar Pharmachem has a ROE of 2.0693%. (Higher is better)

  • Debt to equity ratio: It is a good metric to check out the capital structure along with its performance. Omkar Pharmachem has a Debt to Equity ratio of 0.0328 which means that the company has low proportion of debt in its capital.

  • Sales growth: Omkar Pharmachem has reported revenue growth of 0% which is poor in relation to its growth and performance. 

  • Operating Margin: This will tell you about the operational efficiency of the company. The operating margin of Omkar Pharmachem for the current financial year is 52.4814814814815%.

  • Dividend Yield: It tells us how much dividend we will receive in relation to the price of the stock. The current year dividend for Omkar Pharmachem is Rs 0 and the yield is 0%.

  • Earnings Per Share: It tells us how much profit is allocated to to each outstanding share of a common stock. The latest EPS of Omkar Pharmachem is Rs 0.1755. The higher the EPS, the better it is for investors. 

One can find all the Financial Ratios of Omkar Pharmachem in Ticker for free. Also, one can get the intrinsic value of Omkar Pharmachem by using Valuation Calculators, which are available with a Finology ONE subscription. 

Omkar Pharmachem FAQs

Q1. What is Omkar Pharmachem share price today?
Ans: The current share price of Omkar Pharmachem is Rs 25.56.

Q2. What is the market capitalisation of Omkar Pharmachem?
Ans: Omkar Pharmachem has a market capitalisation of Rs 25.7767488 Cr., calculated based on its latest share price.

Q3. What are the P/E and P/B ratios of Omkar Pharmachem?
Ans: The PE ratio of Omkar Pharmachem is 145.641025641026 and the P/B ratio of Omkar Pharmachem is 2.72483049763336, showing how the stock is valued against its earnings and book value.

Q4. What is the 52-week high and low of Omkar Pharmachem share?
Ans: The 52-week high share price of Omkar Pharmachem is Rs 30.09, and the 52-week low share price of Omkar Pharmachem is Rs 25.56.

Q5. Does Omkar Pharmachem pay dividends?
Ans: Currently, Omkar Pharmachem does not pay dividends. Dividend yield of Omkar Pharmachem is around 0%.

Q6. What are the face value and book value of Omkar Pharmachem shares?
Ans: The face value of Omkar Pharmachem shares is Rs 10, while the book value per share of Omkar Pharmachem is around Rs 9.3804. Face value is the nominal value set by the company, whereas book value reflects its accounting worth.

Q7. What is the debt of Omkar Pharmachem?
Ans: Omkar Pharmachem has a total debt of Rs 0.3031 Cr., which affects investor sentiment and financial stability. 

Q8. What are the ROE and ROCE of Omkar Pharmachem?
Ans: The ROE of Omkar Pharmachem is 2.0693% and ROCE of Omkar Pharmachem is 2.9373%. ROE shows how efficiently the company is generating profit from shareholders’ equity, while the ROCE is reflects how efficiently the company uses its capital to generate returns.

Q9. Is Omkar Pharmachem a good buy for the long term?
Ans: The Omkar Pharmachem long-term outlook depends on debt levels, earnings growth, and sector trends. If it sustains profits and manages debt well, it may be considered for long-term investment.

Q10. Is Omkar Pharmachem undervalued or overvalued?
Ans: Based on valuation ratios like P/E, P/B, and EV/EBITDA, one can analyse whether the Omkar Pharmachem appears undervalued or overvalued at current levels. You can check detailed valuation metrics and peer comparisons on Finology Ticker.

Q11. How to check Omkar Pharmachem’s financials?
Ans: You can review Omkar Pharmachem’s financial statements - including balance sheet, income statement, and quarterly results - on Finology Ticker.

Last Updated on:
Brief about Omkar Pharmachem
X